Women under 45
Women over 45
Special populations: Women with estrogen receptor-positive, HER2-negative, early-stage breast cancer.
A new study shows that chemotherapy use for early-stage, node-positive and node-negative breast cancers declined from 2013 to 2015. It also reports that oncologists’ recommendations are influenced to differing degrees by patient preferences and tumor test results, despite unchanging health care guidelines. (8/21/18)
|At a glance||Guidelines|
|Questions for your doctor||Resources and references|
Why fewer women with early stage breast cancer are undergoing chemotherapy.
Chemotherapy benefits some, but not all people with breast cancer. It can also cause significant side effects. Tumor tests that predict response to treatment (called predictive testing or genomic testing) can help doctors and patients weigh the benefits versus the risks of chemotherapy. Increasingly, oncologists are tailoring their treatment recommendations based on their patient's situation. This study is important because it documents how oncologists are using additional information, including tumor test scores and patient preference, to shape their recommendations for chemotherapy. This is leading to fewer patients receiving chemotherapy for early-stage breast cancer.
Alison Kurian, MD, and colleagues at Stanford University and University of Michigan found that among women with stage 1 or stage 2 estrogen receptor-positive, Her2-negative breast cancer, chemotherapy use declined from 34% in 2013 to 21% in 2015. During this time there were no major changes in U.S. guidelines.
Oncologists were asked their recommendations regarding chemotherapy in two hypothetical cases:
Overall, oncologists took patient preferences into account, using recurrence scoring of tumors to help reconcile differences in patients’ wishes and their recommendations. Whether this trend is warranted remains to be seen.
This trend may reflect improvements in breast cancer outcomes for early-stage disease, increasingly personalized care and concerns about overtreatment.
Oncologists are considering more factors, such as genomic tumor testing and patient preference, when deciding on post-surgical treatment recommendations. It is important to discuss your treatment options with your oncologist. Expressing your preferences, asking whether genomic testing is warranted and describing any family history of cancer will provide your oncologist with a more thorough understanding of your situation and needs.
Share your thoughts on this XRAYS article by taking our brief survey.
The American Society of Clinical Oncology (ASCO) has published guidelines on the use of different biomarker tests to guide decisions on adjuvant chemoatherapy or hormone therapy in early-stage breast cancer. Among their recommendations. Strength of recommendation is noted in parentheses):
Additional information on other tumor types and biomarker tests can be found on the ASCO website.
The National Comprehensive Cancer Network (NCCN) has expert-developed guidelines for treating breast cancer. NCCN guidelins for node-negative, ER-positive, Her2-negative breast cancer includes the following recommendations.
NCCN notes that other prognostic tumor tests are available for treatment decision-making. The NCCN guidelines state that the Oncotype Dx 21-gene panel is preferred by the Breast Cancer Panel for node negative breast cancer.
These guidelins are up-to-date as of 09/28/19.
The following study is looking at tumor prognostic tests used for decision-making in early-stage breast cancer:
Chemotherapy benefits cancer treatment in some, but not all cases. Furthermore, it can cause significant side effects—the balance of benefit and risk of this treatment has changed with greater knowledge in this field, and in particular, our expanding ability to predict outcomes from tumor testing.
Increasingly, oncologists are personalizing cancer care, tailoring treatment to an individual's situation. This study is important because it documents the decline of chemotherapy in the face of unchanged guidelines for care, and oncologists’ use of additional information, including recurrence scores and patient preference, to shape their recommendations for chemotherapy.
Oncologists recommend treatment before or after surgery to remove tumors, based on size and stage, and whether cancer cells are present in the lymph nodes. Patients who have cancer cells in the lymph nodes as well as the primary tumor site are generally considered to have more advanced cancer.
Genomic testing of tumors has improved the ability of oncologists to predict the chance of recurrence (a reappearance of cancer after surgery and treatment). A patient’s recurrence score (RS) is a measure of this prediction:
Another XRAYS review examined results from the TAILORx trial. This study found that women with hormone receptor-positive, HER2-negative, node-negative early-stage breast cancer with Oncotype DX recurrence scores of 11-25 did as well on hormonal therapy alone as those given hormonal therapy plus chemotherapy. Women age 50 or younger with Oncotype DX recurrence scores of 16-25 who received chemotherapy plus hormonal therapy had lower rates of distant recurrence than those who received hormonal therapy alone.
The National Comprehensive Cancer Network publishes chemotherapy guidelines for estrogen receptor-positive tumors. These are baseline guidelines; oncologists have the latitude to adjust their recommendations to individual patient's circumstances.
How chemotherapy use and oncologists' recommendations have changed over time.
Women with early-stage breast cancer and their attending oncologists were surveyed for information about chemotherapy use.
The 5,080 women surveyed were identified from two SEER registries in Georgia and Los Angeles between 2013 and 2015. Selection was made based on date of diagnosis; tumor characteristics, including size, stage, grade, estrogen receptor and HER2 status, and whether patients had recurrence score testing.
The women ranged in age from 20-79 years and were diagnosed with stage 0-2 breast cancer. The group of women were 56% white, 16% black, 17% Hispanic and 8% Asian. Among those surveyed, 2,926 met the study criteria with stage 1 or 2 estrogen receptor-positive, Her2-negative breast cancer. (Stage 0 breast cancer patients were excluded, as chemotherapy is not standardly recommended.)
Among 504 oncologists identified for these patients, 304 completed surveys about their responses to node-negative and node-positive case scenarios.
Chemotherapy use among women with early-stage breast cancer:
Women with stage 1 or 2 estrogen receptor-positive, Her2-negative breast cancer were surveyed about their age at diagnosis, whether they met with an oncologist, received chemotherapy and whether their oncologist recommended chemotherapy.
Among these women, chemotherapy use declined from 34% in 2013 to 21% in 2015. During this time there were no major changes in U.S. guidelines.
Estimating recurrence is conducted with a 21-gene panel test of tumors. Low tumor recurrence scores (RS) indicate that there is a low probability of recurrence. High tumor RS indicates that there is a higher probability of recurrence. Use of RS changed the frequency that chemotherapy was used for node-positive but not node-negative patients:
Recommendations of oncologist in response to case scenarios:
Researchers presented oncologists with two hypothetical case scenarios:
1) A 60-year-old, postmenopausal patient with a 0.7 mm tumor who was node-negative.
2) A 48-year-old, premenopausal patient with a 2.2 cm tumor who was node positive.
Oncologists were asked for their recommendations regarding chemotherapy:
For the first case (a more favorable disease situation):
For the second case (a less favorable disease situation):
Overall, oncologists considered patient preferences when ordering tests or recommending treatment, particularly if patient wishes disagreed with their original recommendations. Oncologists used recurrence scoring to help reconcile differences in patients’ wishes and their recommendations. Whether this trend is warranted remains to be seen.
This study has a few limitations. First, the data on chemotherapy use relies on patient reports rather than more direct measures (e.g. patient medical records).
The number of node-positive cases were smaller (420 or 14% of all cases) than node-negative cases (over 2,000). There was no detail on lymph node number, size, or specific chemotherapy agents recommended. More details would allow a more nuanced understanding of oncologist recommendations.
The study took place over a relatively short period (two years) in only 2 geographic locations, and oncologists were surveyed only once. It is unclear if oncologists' recommendations would differ depending on geographic location or whether recommendations would change more (or less) with increased time interval and more reflection.
Chemotherapy use substantially and significantly decreased over the 2-year evaluation period, despite a lack of changes in national guidelines. The decline in use may reflect improvements in breast cancer outcomes for early-stage disease, increasingly personalized care and concerns about overtreatment. Oncologists were responsive to patient preferences in their recommendations about chemotherapy, and in particular, their willingness to pursue genomic testing of tumors to clarify prognosis. In the face of genomic test results that ran counter to initial chemotherapy plans, many oncologists adjusted their recommendations.
Share your thoughts on this XRAYS article by taking our brief survey.